New England Research & Management’s BioMarin Pharmaceuticals BMRN Stock Holding History

New England Research & Management’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-13,625	Closed	-$958K	–	149
2024 Q3	$958K	Buy	13,625 +4,550	+50%	+$380K	0.45%	72
2024 Q2	$747K	Sell	9,075 -6,275	-41%	-$522K	0.36%	88
2024 Q1	$1.34M	Buy	+15,350	New	+$1.37M	0.66%	51
2023 Q2	–	Sell	-9,550	Closed	-$929K	–	138
2023 Q1	$929K	Buy	+9,550	New	+$990K	0.54%	71
2022 Q2	–	Sell	-9,363	Closed	-$722K	–	155
2022 Q1	$722K	Buy	9,363 +4,351	+87%	+$364K	0.37%	85
2021 Q4	$443K	Buy	+5,012	New	+$414K	0.21%	117
2021 Q1	–	Sell	-6,750	Closed	-$592K	–	170
2020 Q4	$592K	Buy	+6,750	New	+$535K	0.37%	89
2019 Q3	–	Sell	-3,150	Closed	-$270K	–	165
2019 Q2	$270K	Sell	3,150 -350	-10%	-$29.9K	0.18%	142
2019 Q1	$311K	Buy	+3,500	New	+$324K	0.21%	128
2018 Q4	–	Sell	-5,500	Closed	-$533K	–	157
2018 Q3	$533K	Buy	+5,500	New	+$549K	0.35%	101

Other funds holding BMRN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

EIM

Elliott Investment Management West Palm Beach, Florida $20.1B AUM 60.76% 1-Year Est. Return

New England Research & Management's BMRN Position: Q4 2024 in Review

New England Research & Management sold out of BioMarin Pharmaceuticals (BMRN) in Q4 2024, closing a stake of 13,625 shares — an estimated $958K sold.

New England Research & Management first reported a position in BMRN in Q3 2018 and held it in 10 quarters. The position peaked at $1.34M in Q1 2024. 543 funds tracked by Wall St. Rank hold BMRN as of Q4 2024.

New England Research & Management reported no remaining BioMarin Pharmaceuticals position as of Q4 2024 after selling out during the quarter.
New England Research & Management sold 13,625 BioMarin Pharmaceuticals shares in Q4 2024, an estimated $958K.
New England Research & Management first reported a position in BioMarin Pharmaceuticals in Q3 2018 and held it in 10 quarters.
New England Research & Management's BioMarin Pharmaceuticals position peaked at $1.34M in Q1 2024.
543 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q4 2024.

Based on New England Research & Management's 13F filing for Q4 2024, filed 23 Jan 2025.